- Home
- FOA vs INMB Comparison
FOA vs INMB Comparison
Compare FOA & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FOA | INMB |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.6M | 57.9M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | FOA | INMB |
|---|---|---|
| Price | $21.76 | $2.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $26.00 | $5.40 |
| AVG Volume (30 Days) | 41.3K | ★ 354.0K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 216.95 | 11.85 |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $497,432,000.00 | $50,000.00 |
| Revenue This Year | $0.58 | N/A |
| Revenue Next Year | $6.91 | N/A |
| P/E Ratio | $54.41 | ★ N/A |
| Revenue Growth | 47.09 | ★ 257.14 |
| 52 Week Low | $15.77 | $1.09 |
| 52 Week High | $29.79 | $2.58 |
Technical Indicators
Market Signals| Indicator | FOA | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 45.00 | 65.83 |
| Support Level | $22.10 | $1.37 |
| Resistance Level | $24.03 | $2.17 |
| Average True Range (ATR) | 1.12 | 0.12 |
| MACD | -0.15 | 0.02 |
| Stochastic Oscillator | 22.92 | 88.89 |
Price Performance
Historical ComparisonAbout FOA Finance of America Companies Inc.
Finance of America Companies Inc provides home equity-based financing solutions for modern retirement and offers capital markets and portfolio management capabilities to optimize loan distribution to investors. The Company operates through two segments: Retirement Solutions and Portfolio Management. The Retirement Solutions segment handles loan origination, including HECM and non-agency reverse mortgage loans, generating revenue from origination fees and initial gains, with loans transferred to the Portfolio Management segment. The Portfolio Management segment, which generates the majority of revenue, provides securitization, loan sales, risk management, and asset management services, and earns revenue from net interest income, fair value changes, and servicing-related income.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.